Insider Trading March 12, 2026

Doximity interim PFO sells Class A stock worth $58,833; firm posts beat amid mixed analyst views

Sitaram Siddharth executed an automatic sale under a 10b5-1 plan, converted Class B shares and exercised options as the company reported stronger-than-expected quarterly results

By Priya Menon DOCS
Doximity interim PFO sells Class A stock worth $58,833; firm posts beat amid mixed analyst views
DOCS

Interim principal financial officer and principal accounting officer Sitaram Siddharth sold 2,319 shares of Doximity Class A common stock on March 10, 2026, through an automatic Rule 10b5-1 plan for proceeds of $58,833. On the same day he converted 5,000 Class B shares into Class A shares and exercised 5,000 options at a $4.12 strike. Doximity’s shares are trading near their 52-week low and have fallen 66% over six months, even as the company posted fiscal third-quarter revenue and EBITDA above guidance and consensus; analysts have issued a range of reactions on price targets and ratings.

Key Points

  • Interim PFO Sitaram Siddharth sold 2,319 Class A shares under a Rule 10b5-1 plan for $58,833 and converted 5,000 Class B shares to Class A while exercising 5,000 options at $4.12.
  • Doximity reported fiscal Q3 revenue and EBITDA that exceeded guidance and consensus by $4.6 million and $7.9 million, respectively.
  • Analysts reacted variably: Canaccord upgraded to Buy but lowered its target to $34.00; Piper Sandler raised its target to $42.00 and kept Overweight; Mizuho and BMO cut targets to $34.00 and $25.00, respectively.

Transaction details

Sitaram Siddharth, serving as interim principal financial officer and principal accounting officer of Doximity, Inc. (NASDAQ:DOCS), sold 2,319 shares of Class A Common Stock on March 10, 2026. The shares were sold at $25.37 each for total gross proceeds of $58,833. The disposition occurred automatically under a Rule 10b5-1 trading arrangement.


Share-class conversions and option exercise

Also on March 10, Siddharth converted 5,000 shares of Class B Common Stock into Class A Common Stock. In addition, he acquired 5,000 shares through the exercise of stock options carrying an exercise price of $4.12.


Market context and valuation signals

At the time reporting the transaction, Doximity shares were trading at $24.28, slightly above the company’s 52-week low of $23.53. According to analysis cited in the report, the shares have declined 66% over the past six months. The same analysis indicates the stock appears undervalued at current levels and highlights that Doximity maintains gross profit margins near 90% - one of more than a dozen tips noted for subscribers to the referenced analysis service.


Quarterly performance and analyst reactions

Doximity reported fiscal third-quarter results in which revenue and EBITDA outperformed both the company’s guidance and consensus estimates by $4.6 million and $7.9 million, respectively. The stronger-than-expected quarterly metrics have prompted a variety of responses from equity analysts:

  • Canaccord Genuity upgraded Doximity to a Buy rating on valuation grounds, while lowering its price target from $48.00 to $34.00.
  • Piper Sandler raised its price target to $42.00 and maintained an Overweight rating, citing an assessment of Doximity’s suite of AI tools.
  • Mizuho trimmed its price target to $34.00 but kept a Neutral rating, noting delays in pharmaceutical marketing budgets as a factor.
  • BMO Capital reduced its price target to $25.00, flagging near-term headwinds while acknowledging that the quarter beat expectations.

Takeaway

The insider sale executed under an automatic trading plan was accompanied by share-class conversion and option exercises by Siddharth. The company’s recent quarterly outperformance coexists with a steep six-month stock decline and mixed analyst assessments, reflecting divergent views on near-term headwinds and valuation. The data presented here is limited to the reported transactions, market prices, quarterly beat amounts and the stated analyst actions.


Risks

  • Shares trading near the 52-week low and down 66% over six months present market-price risk for investors - impacts equity investors and capital markets.
  • Analyst divergence on price targets and ratings indicates uncertainty about near-term valuation and demand drivers - impacts sell-side research and investor sentiment.
  • Delays in pharmaceutical marketing budgets, as cited by Mizuho, create revenue risk for Doximity’s business tied to pharmaceutical advertising and marketing - impacts healthcare marketing spend and related technology providers.

More from Insider Trading

Citi Trends Director Reduces Stake with $91,820 Sale as Shares Rally and Valuation Questions Loom Apr 7, 2026 RENN Fund President Murray Stahl Buys 1,134 Shares Apr 7, 2026 Darden Group President Disposes Nearly $1 Million in Stock After Option Exercise Apr 7, 2026 Teradyne Director Disposes of 625 Shares as Company Rides Strong 12‑Month Rally Apr 7, 2026 Kohl’s Chief People Officer Makes Small Automated Sale as Company Posts Mixed Q4 Results Apr 7, 2026